Skip to main content
hello world

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Kura Oncology Reports Second Quarter 2022 Financial Results

Globe Newswire - Wed Aug 3, 2022

– Recommended Phase 2 dose for ziftomenib identified, pending FDA review –

– Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML –

Read more at globenewswire.com